Silver Book Fact

A study of Parkinson’s disease treatments found that pramipexole is a cost-effective treatment for early and advanced Parkinson’s disease. The total cost-effectiveness ratio was $8,837/QALY for patients with early Parkinson’s disease and $12,294/QALY for patients with advanced disease.

Hoerger T, Bala M, Rowland C, Greer M, et al. Cost Effectiveness of Pramipexole in Parkinson’s Disease in the U.S. Pharmacoeconomics. 1998; 14(5): 541-57. http://www.ncbi.nlm.nih.gov/pubmed/10344917

Reference

Title
Cost Effectiveness of Pramipexole in Parkinson’s Disease in the U.S.
Publication
Pharmacoeconomics
Publication Date
1998
Authors
Hoerger T, Bala M, Rowland C, Greer M, et al.
Volume & Issue
Volume 14, Issue 5
Pages
541-57
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • If the progression of Parkinson’s disease were slowed by 50%, there would be a 35% reduction in excess costs.  
  • According to one Parkinson’s expert, a 10% slowing of Parkinson’s disease progression would save $327 million per year.  
  • According to the Pharmaceutical Research and Manufacturers of America, 21 new medicines are currently in development for the treatment of Parkinson’s disease.  
  • In one study, Alzheimer’s patients who took donepezil had an increase in their prescription costs of $1,000 per patient, but saw reduced total medical costs of about 1/3–from $11,947 to…  
  • If an Alzheimer’s disease treatment breakthrough that delayed the age of onset by 5 years was introduced in 2015, by 2020 total cost of care (for all payers) for all people…